Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607404 | 0.79 | TSHR (0.31) | SMN1; SMN2 | |
| SCHEMBL1972998 | 0.74 | DNM1 (0.33) | — | |
| SCHEMBL21925359 | 0.73 | DNM1 (0.36) | SMN1; SMN2 | |
| SCHEMBL17607464 | 0.72 | METAP1 (0.31) | — | |
| SCHEMBL29219038 | 0.71 | OPRM1 (0.39) | — | |
| SCHEMBL1780703 | 0.71 | DNM1 (0.31) | — | |
| SCHEMBL10772240 | 0.71 | DNM1 (0.38) | SMN1; SMN2 | |
| SCHEMBL1970811 | 0.71 | DNM1 (0.38) | SMN1; SMN2 | |
| SCHEMBL24938316 | 0.70 | OPRM1 (0.37) | — | |
| SCHEMBL17607768 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635887-A | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | WARNER LAMBERT CO (US) | 2005-07-06 | — | — | CN | disclosed |
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | TAYLOR CHARLES PRICE (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | CACNG2, GABRB2, CACNG4 | MAPT 1966/4885SMN1; SMN2 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.